NasdaqGS - Nasdaq Real Time Price USD

AstraZeneca PLC (AZN)

71.20

+0.35

(+0.49%)

At close: 4:00 PM EDT

71.82

+0.62

(+0.87%)

After hours: 5:12 PM EDT

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Zacks yesterday

AZN
+0.49%
BMRN
With 85% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing

Key Insights Given the large stake in the stock by institutions, AstraZeneca's stock price might be vulnerable to their...

Simply Wall St. 2 days ago

AZN
+0.49%
AZNCF
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Astrazeneca (AZN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Zacks 2 days ago

AZN
+0.49%
11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Best Low Price Pharma […]

Insider Monkey 3 days ago

^GSPC

AZN
+0.49%
SWAV
20 Countries with the Highest Cancer Survival Rates in the World

In this article, we will be taking a look at the 20 countries with the highest cancer survival rates in the world. If you do not want to learn about the cancer treatment in the US, head straight to the 5 Countries with the Highest Cancer Survival Rates in the World. Navigating the Terrain: The […]

Insider Monkey 5 days ago

ILMN

AZN
+0.49%
Astrazeneca (AZN) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.

Zacks 6 days ago

AZN
+0.49%
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).

Business Wire 8 days ago

AZN
+0.49%
AZNCF
3 Pharma Stocks That Are Money-Printing Machines in 2024

The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy’s resilience. The well established pharmaceutical industry continues to assert its economic dominance through resolute financials. In 2022, pharma stocks brought in $510.5 billion, with forecasts for the sector to reach $863.6 billion in revenue by 2030. Between 2023 and 2030, the industry

InvestorPlace 8 days ago

NVO

AZN
+0.49%
CELG-RT
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Amazing deals can still be found by opportunistic investors, even with the Nasdaq Composite reaching new heights.

Motley Fool 10 days ago

COMP

PUBM

V
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.

Zacks 12 days ago

AZN
+0.49%
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.

Zacks 12 days ago

SWAV

PFE

AZN
+0.49%
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

Astrazeneca (AZN) closed the most recent trading day at $69.45, moving +1.97% from the previous trading session.

Zacks 12 days ago

AZN
+0.49%
^GSPC
AstraZeneca hit by investor backlash over chief Pascal Soriot’s £19m pay deal

AstraZeneca has suffered an investor backlash over a £19m pay award for its chief executive, in a vote that will deepen concerns of an exodus of UK companies to the US.

The Telegraph 13 days ago

AZN
+0.49%
LNSTY
World risks ‘tepid Twenties’ as debt levels and inflation soar, warns IMF

The world is at risk of a “sluggish and disappointing decade”, the head of the International Monetary Fund has warned, while urging vigilance to restore price stability and jumpstart economic growth.

The Telegraph 13 days ago

^FTSE

^YH101

AZN
+0.49%
AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

High executive pay in Britain has long been contentious, particularly with pay for ordinary workers rising far more slowly, and Soriot's pay package has proved a lightning rod for investor discontent in the past. In 2021 — the last time AstraZeneca's long-term incentives policy was reviewed — almost 40% of votes were cast against it, and proxy advisory groups Glass Lewis and ISS also opposed the plan, as they did this year. Despite the notable no votes, the final result is a major boost to one of the best-paid executives among London's blue-chip FTSE 100 at a time when British firms are looking to match U.S. and European rivals' pay packages.

Reuters 13 days ago

AZN
+0.49%
^FTSE
UPDATE 2-AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

AstraZeneca shareholders on Thursday approved a 2024 pay policy which will boost CEO Pascal Soriot's remuneration to as much as 18.9 million pounds ($23.7 million) this year, but over a third of investors revolted against the huge sum. High executive pay in Britain has long been contentious, particularly with pay for ordinary workers rising far more slowly, and Soriot's pay package has proved a lightning rod for investor discontent in the past. In 2021 — the last time AstraZeneca's long-term incentives policy was reviewed — almost 40% of votes were cast against it, and proxy advisory groups Glass Lewis and ISS also opposed the plan, as they did this year.

Reuters 13 days ago

AZN
+0.49%
^FTSE
FASENRA approved for treatment of children aged 6 to 11 with severe asthma

WILMINGTON, Del., April 11, 2024--AstraZeneca’s FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged 12 and older.1

Business Wire 13 days ago

AZN
+0.49%
AZNCF
Trending tickers: Darktrace, AstraZeneca, Persimmon, Bitcoin

The latest investor updates on stocks that are trending on Thursday.

Yahoo Finance UK 13 days ago

PSMMF

PSMMY

BTC-USD
CORRECTED-UPDATE 1-European shares dip ahead of ECB policy decision

European shares slipped on Thursday as investors avoided big bets ahead of a monetary policy decision by the European Central Bank and remarks by ECB's Christine Lagarde on the outlook for interest rate cuts. The pan-European STOXX 600 lost 0.3%, as of 0906 GMT.

Reuters 13 days ago

^FCHI

^FTSE

IDIA.SW
AstraZeneca promises dividend rise ahead of vote on chief’s £18.7m pay deal

The update came ahead of AstraZeneca’s annual general meeting on Thursday afternoon.

PA Media: Money 13 days ago

AZN
+0.49%

Performance Overview

Return	AZN	FTSE 100
YTD	+7.34%	+3.97%
1-Year	-3.75%	+1.60%
3-Year	+45.77%	+15.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZN)

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

With 85% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing

Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics

11 Best Low Price Pharma Stocks To Invest In

20 Countries with the Highest Cancer Survival Rates in the World

Astrazeneca (AZN) Could Be a Great Choice

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

3 Pharma Stocks That Are Money-Printing Machines in 2024

4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

AstraZeneca hit by investor backlash over chief Pascal Soriot’s £19m pay deal

World risks ‘tepid Twenties’ as debt levels and inflation soar, warns IMF

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

UPDATE 2-AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Trending tickers: Darktrace, AstraZeneca, Persimmon, Bitcoin

CORRECTED-UPDATE 1-European shares dip ahead of ECB policy decision

AstraZeneca promises dividend rise ahead of vote on chief’s £18.7m pay deal

Performance Overview